```html

Noval Atypical Hemolytic Uremic Syndrome (aHUS)

Overview

Noval atypical hemolytic uremic syndrome (aHUS) is a rare, life‑threatening disorder that causes the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. Unlike the classic (typical) form that follows an infection with Shiga‑toxin‑producing E. coli, the “atypical” variant is driven by uncontrolled activation of the complement system – a part of the immune system that normally helps destroy pathogens.

The term “Noval” is used in the recent literature to describe a subset of aHUS patients who harbor newly identified genetic or acquired complement‑regulatory abnormalities that were not captured in earlier classification schemes. The disease can affect children and adults, but incidence peaks in early childhood (≈ 2–5 years) and again in young adulthood (20‑35 years).

Overall, aHUS accounts for ≈ 5–10 % of all hemolytic‑uremic syndrome cases. The estimated prevalence in the United States is about 2–3 per million people, which translates to roughly 600‑900 individuals nationwide [1] NIH. Worldwide incidence is similarly low, with slight regional variation due to differences in genetic background.

Symptoms

The clinical picture can evolve rapidly (hours to days) and varies according to which organs are involved. Below is a comprehensive list of reported symptoms, grouped by system.

Hematologic (blood‑related) symptoms

• Fatigue and weakness – result of anemia caused by destruction of red blood cells.
• Pale skin or mucous membranes – due to low hemoglobin.
• Bruising, petechiae, or easy bleeding – low platelet count (thrombocytopenia) impairs clot formation.
• Dark urine (hemoglobinuria) – free hemoglobin released from lysed red cells gives urine a tea‑colored appearance.

Renal (kidney) symptoms

• Decreased urine output (oliguria) or complete lack of urine (anuria).
• Swelling (edema) of the legs, face, or abdomen caused by fluid retention.
• Hypertension – high blood pressure appears in up to 70 % of patients at presentation [2] Mayo Clinic.
• Pain in the flank or lower back – kidney capsule stretch.

Gastrointestinal symptoms

• Nausea, vomiting, or abdominal pain – may mimic gastroenteritis.
• Diarrhea (usually non‑bloody); unlike typical HUS, diarrhea is not a precipitating factor.

Neurologic symptoms (seen in 20‑30 % of cases)

• Headache, confusion, or altered mental status.
• Seizures or focal neurological deficits (e.g., weakness on one side).

Cardiovascular symptoms

• Chest pain or shortness of breath from fluid overload or hypertension‑related cardiac strain.

Other possible manifestations

• Pancreatitis, liver enzyme elevation, and rare pulmonary hemorrhage have been reported, especially in severe complement activation.

Causes and Risk Factors

Underlying pathophysiology

aHUS is fundamentally a disorder of complement regulation. The alternative pathway of complement is continuously active at a low level; regulatory proteins (e.g., factor H, factor I, membrane cofactor protein [MCP/CD46], and thrombomodulin) keep it in check. Mutations or auto‑antibodies that impair these regulators lead to persistent activation, endothelial injury, platelet aggregation, and the formation of micro‑thrombi that occlude small vessels—principally in the kidneys.

Genetic causes (≈ 50‑60 % of patients)

• CFH (complement factor H) mutations – most common, found in 20‑30 % of aHUS cases.
• CFI (factor I) and CD46 (MCP) mutations – each accounts for ~10 %.
• C3 and CFB gain‑of‑function mutations – less common but associated with earlier disease onset.
• Thrombomodulin (THBD) mutations – linked to milder renal disease.

Acquired (auto‑immune) causes (≈ 10‑20 %)

• Anti‑factor H antibodies – most prevalent in children; often associated with preceding infections or vaccination.
• Other auto‑antibodies targeting complement components (rare).

Triggering events

Even with a genetic predisposition, a “second hit” often precipitates disease onset:

• Infections (especially respiratory or urinary tract).
• Pregnancy or postpartum period.
• Major surgery or organ transplantation.
• Certain medications (e.g., calcineurin inhibitors, monoclonal antibodies).
• Vaccinations (temporally related in a minority of cases).

Who is at higher risk?

• First‑degree relatives of a patient with a known complement mutation.
• Individuals with a personal or family history of aHUS, atypical thrombotic microangiopathy, or complement‑mediated renal disease.
• Patients with systemic autoimmune diseases (e.g., systemic lupus erythematosus) who develop complement dysregulation.

Diagnosis

Because aHUS mimics other thrombotic microangiopathies (TMA) such as thrombotic thrombocytopenic purpura (TTP) and typical HUS, a rapid, systematic work‑up is essential.

Initial laboratory assessment (performed within hours)

• Complete blood count (CBC) – look for anemia (low Hgb) and thrombocytopenia.
• Peripheral blood smear – presence of schistocytes (fragmented RBCs) confirms microangiopathic hemolysis.
• Serum lactate dehydrogenase (LDH) – markedly elevated due to cell rupture.
• Haptoglobin – usually undetectable in hemolysis.
• Serum creatinine & BUN – evaluate renal function; creatinine often rises rapidly.
• Urinalysis – hematuria, proteinuria, and possibly red‑cell casts.

Excluding other TMAs

• ADAMTS13 activity – <10 % activity suggests TTP; >10 % makes TTP unlikely.
• Stool culture or PCR for Shiga toxin – positive in typical HUS, negative in aHUS.
• Coombs test – usually negative in aHUS (helps rule out autoimmune hemolytic anemia).

Complement studies

• C3/C4 levels – often low or normal; not diagnostic alone.
• Functional assays (e.g., CH50, AH50) – may show reduced activity of the alternative pathway.

Genetic testing

Targeted next‑generation sequencing panels that include CFH, CFI, CD46, C3, CFB, THBD, and anti‑factor H antibody testing are recommended once the patient is stable. Results can take weeks, so treatment should not be delayed while awaiting genetics.

Kidney imaging and biopsy

• Renal ultrasound – assesses size and excludes obstruction.
• Kidney biopsy (rarely needed) – shows thrombotic microangiopathy; helps when diagnosis remains uncertain.

Diagnostic criteria (simplified)

A diagnosis of Noval aHUS is made when all three core features are present (hemolytic anemia, thrombocytopenia, acute kidney injury) **and**:

1. ADAMTS13 activity >10 %;
2. No evidence of Shiga‑toxin infection;
3. Evidence of complement dysregulation (genetic mutation or anti‑factor H antibodies) OR a strong clinical suspicion when genetic testing is pending.

Treatment Options

Prompt therapy dramatically improves renal recovery and survival. The cornerstone of modern care is targeted complement inhibition, complemented by supportive measures.

1. Complement‑targeted therapy

• Eculizumab (Soliris®) – a monoclonal antibody that blocks C5, halting terminal complement activation. Approved for aHUS in 2011. Dosing: weekly infusions (900 mg) for 4 weeks, then 1200 mg every 2 weeks. Evidence*: > 80 % of treated adults achieve platelet normalization within 2 weeks; > 70 % avoid dialysis [3] NEJM 2013.
• Ravulizumab (Ultomiris®) – a long‑acting C5 inhibitor allowing dosing every 8 weeks after loading. Similar efficacy with fewer infusions, improving quality of life.
• Both drugs increase susceptibility to encapsulated bacteria, especially Neisseria meningitidis. Vaccination (meningococcal conjugate, serogroups A, C, W, Y and optionally B) should be administered at least 2 weeks before initiation, or prophylactic antibiotics given if urgent treatment is needed.

2. Plasma therapy (historical)

Before complement inhibitors, plasma exchange (PLEX) or plasma infusion was the mainstay. PLEX can temporarily supply functional complement regulators, but response rates are modest (≈ 30‑40 %) and it carries risks (allergic reactions, volume overload). Current guidelines reserve plasma therapy for patients who cannot receive eculizumab/ravulizumab or while awaiting approval [4] KDIGO 2021.

3. Supportive care

• Renal replacement therapy (RRT) – dialysis (hemodialysis or peritoneal) when creatinine rises > 3 mg/dL or oliguria persists.
• Blood pressure control – ACE inhibitors or ARBs are first‑line to protect kidneys and reduce cardiovascular strain.
• Transfusion support – packed RBCs for symptomatic anemia; platelet transfusions only if life‑threatening bleeding.
• Fluid management – careful balance to avoid volume overload while maintaining renal perfusion.

4. Lifestyle and adjunct measures

• Vaccinations (influenza, pneumococcal, meningococcal) as per immunization schedule.
• Prompt treatment of infections – early antibiotics for urinary or respiratory infections.
• Avoidance of known triggers (e.g., certain chemotherapeutic agents or calcineurin inhibitors) when possible.

Living with Noval atypical hemolytic uremic syndrome

Medication adherence

Because eculizumab/ravulizumab are given intravenously, most patients arrange monthly infusion visits at an infusion center or at home via a nurse. Missing a dose can lead to rapid disease relapse; set reminders and keep a medication calendar.

Monitoring schedule

• Every 1–2 weeks (initial phase): CBC, LDH, creatinine, blood pressure.
• Every 1–3 months (stable phase): same labs plus urinalysis for proteinuria.
• Annually: complement activity panel and genetic counseling review.

Renal health

Even with successful complement inhibition, some patients develop chronic kidney disease (CKD). Nephrology follow‑up, low‑salt diet, and avoidance of nephrotoxic drugs (NSAIDs, contrast agents) are essential.

Psychosocial considerations

• Connect with patient support groups (e.g., aHUS Foundation). Sharing experiences reduces anxiety and improves coping.
• Consider counseling for chronic illness stress, especially in children and adolescents.
• Insurance navigation: document diagnosis, genetic results, and treatment plan to secure coverage for high‑cost biologics.

Pregnancy

Women with aHUS can have successful pregnancies, but they are at higher risk for relapse, especially postpartum. Close monitoring by a multidisciplinary team (nephrology, obstetrics, hematology) and continuation of complement inhibition (often with ravulizumab due to its longer dosing interval) are recommended [5] Am J Kidney Dis 2022.

Prevention

Because the disease is largely genetically driven, true primary prevention is limited. However, risk can be reduced by:

• Vaccination against meningococcus before starting complement inhibitors.
• Early treatment of infections – particularly urinary and respiratory infections that can act as triggers.
• Avoiding known drug precipitants (e.g., high‑dose calcineurin inhibitors) when alternative therapies exist.
• Family screening – relatives of a patient should be offered genetic counseling and, if a pathogenic mutation is identified, baseline complement testing even before symptoms appear.
• Pre‑emptive complement inhibition – in patients with known high‑risk mutations who have previously relapsed, some clinicians maintain prophylactic eculizumab/ravulizumab during high‑risk periods (pregnancy, surgery).

Complications

If aHUS is not promptly controlled, the following complications may arise:

• End‑stage renal disease (ESRD) – occurs in 30‑50 % of untreated patients within months.
• Chronic hypertension – often refractory and a major cardiovascular risk factor.
• Recurrent TMA episodes – each flare can cause cumulative organ damage.
• Neurologic sequelae – stroke, seizures, or persistent cognitive deficits.
• Cardiomyopathy – due to sustained hypertension and microvascular injury.
• Pregnancy loss – miscarriage, preeclampsia, or fetal growth restriction.
• Infection risk – especially meningococcal sepsis in patients on complement inhibitors.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department if you experience any of the following:

• Sudden decrease in urine output or complete lack of urine.
• Severe, worsening shortness of breath or chest pain.
• Rapidly rising blood pressure (≥ 180/120 mmHg) with headache, vision changes, or confusion.
• Unexplained bruising, bleeding, or a sudden drop in platelet count (if you have recent lab results).
• High fever (> 38.5 °C) with chills, especially if you have a known complement inhibitor in place.
• New neurological symptoms – seizure, slurred speech, weakness on one side.

These signs may indicate a relapse or a life‑threatening complication that requires immediate plasma exchange, dialysis, or urgent adjustment of complement therapy.

References

1. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). “Atypical Hemolytic Uremic Syndrome.” Updated 2023. https://www.niddk.nih.gov/…
2. Mayo Clinic. “Atypical hemolytic‑uremic syndrome (aHUS).” Accessed May 2024. https://www.mayoclinic.org/…
3. Legendre CM, et al. “Eculizumab in Atypical Hemolytic‑Uremic Syndrome.” New England Journal of Medicine. 2013;368:228‑236. DOI:10.1056/NEJMoa1209385.
4. KDIGO Clinical Practice Guideline for Thrombotic Microangiopathy. Kidney International Supplements. 2021.
5. Shepherd A, et al. “Management of aHUS in Pregnancy.” American Journal of Kidney Diseases. 2022;80(4):565‑576.

```